| __timestamp | Intra-Cellular Therapies, Inc. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 2917513 |
| Thursday, January 1, 2015 | 18187286 | 7878291 |
| Friday, January 1, 2016 | 24758063 | 8366794 |
| Sunday, January 1, 2017 | 23666957 | 6610381 |
| Monday, January 1, 2018 | 30099855 | 6556000 |
| Tuesday, January 1, 2019 | 64947625 | 6930000 |
| Wednesday, January 1, 2020 | 186363444 | 8758000 |
| Friday, January 1, 2021 | 272611040 | 10806000 |
| Saturday, January 1, 2022 | 358782000 | 9844000 |
| Sunday, January 1, 2023 | 409864000 | 13481000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Intra-Cellular Therapies, Inc. and Soleno Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Intra-Cellular Therapies saw a staggering increase in SG&A expenses, growing nearly 4,000% from 2014 to 2023. In contrast, Soleno Therapeutics maintained a more stable trajectory, with expenses increasing by approximately 360% over the same period.
This divergence highlights the strategic choices each company has made. While Intra-Cellular Therapies has aggressively expanded its operations, reflected in its rising costs, Soleno Therapeutics has opted for a more conservative approach. Understanding these trends offers valuable insights into how biotech firms balance growth and cost management in a rapidly evolving industry.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Bio-Techne Corporation
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Geron Corporation Trends and Insights
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for HUTCHMED (China) Limited and Soleno Therapeutics, Inc.